A Cleveland Clinic physician defines the elusive term
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/ee1a6dcd-3c3a-4afb-88aa-bc9dbc0491eb/Dr_Kalaycia_650x450_jpg)
Dr.Kalaycia_650x450
Matt Kalaycio, MD, Chair of the Department of Hematology and Medical Oncology at Cleveland Clinic, offers principles to help the healthcare industry enable high reliability at the system and individual level in his latest editorial in Hematology News. Dr. Kalaycio, Editor in Chief of the publication, describes the disconnect between physicians and administrators when defining and prioritizing high reliability.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“When the Joint Commission on Accreditation of Healthcare Organizations came to our hospital for a survey last fall, our administration was confident that the review would be favorable. The Joint Commission was stressing the reliability of hospitals and so were we. We had chartered a “High-Reliability Organization Enterprise Steering Committee” that was “empowered to make recommendations to the (executive board) on what is needed to achieve the goals of high reliability across the enterprise.” High reliability was a priority for our administration and for the Joint Commission. Unfortunately, nearly no one else knew what high reliability meant.
When physicians think about reliability, we think about reproducibility and precision. What often is less clear, then, is what our administrators mean when they discuss the importance of “high reliability” in a hospital or health care system.”
Dr. Kalaycio offers five principles for organizations wanting to achieve high reliability, defined as reliable prevention or error, adapted from Managing the Unexpected: Resilient Performance in the Age of Uncertainty.
For individuals, Dr. Kalaycio argues that five similar principles, adapted from Unaccountable: What Hospitals Won’t Tell You and How Transparency Can Revolutionize Health Care, apply:
Advertisement
For more from Dr. Kalaycio on high reliability, read his editorial in Hematology News.
Advertisement
Advertisement
Dotatate PET/CT scan and molecular testing informed treatment trajectory
A proactive, framework-based approach
Patients on ibrutinib were more than twice as likely to experience atrial fibrillation or heart failure than those on second-generation alternatives.
Expert recommendations introduce use of targeted agents
Combination therapy may soon represent new standard of care
Research findings offer clues for improving disease outcomes in men
Creating a safe space for patients
Long-term immune effects reshape preventative strategies and timelines